I think it is interesting that some of the trial data is being released a couple weeks before the conference. I would think conferences would embargo until after the conference. I think this is very good because anyone going to the conference has a good idea of what they want to check out. As the only drug that has shown a drop in liver scarring, I would think we are in the top spot for attendees wanting to stop by. Maybe, the conference will upgrade us from poster to presenter?